Survodutide vs Tirzepatide
Boehringer Ingelheim's GLP-1/glucagon dual agonist versus Eli Lilly's GIP/GLP-1 dual agonist for obesity and metabolic disease.
Last updated: January 28, 2026
Survodutide
Tirzepatide
Overview
Survodutide and tirzepatide represent two different approaches to dual-hormone agonism for metabolic disease. While tirzepatide targets GIP and GLP-1 receptors, survodutide targets glucagon and GLP-1 receptors. Both aim to enhance weight loss and metabolic outcomes beyond single-agonist GLP-1 therapies.
This comparison matters because both compounds demonstrate significant weight loss potential, but through distinct mechanisms that may have different implications for efficacy and safety.
Key Facts
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| Developer | Boehringer Ingelheim | Eli Lilly |
| Targets | GLP-1 + Glucagon | GIP + GLP-1 |
| FDA Status | Phase 3 (not approved) | FDA approved |
| Administration | Subcutaneous injection | Subcutaneous injection |
Mechanism Comparison
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| GLP-1 Activity | Agonist | Agonist |
| Second Target | Glucagon receptor | GIP receptor |
| Unique Feature | Glucagon increases energy expenditure | GIP amplifies GLP-1 effects |
| Metabolic Action | Thermogenesis + appetite | Insulin secretion + appetite |
Survodutide Mechanism
The glucagon component of survodutide is theorized to:
- Increase hepatic glucose output (counterbalanced by GLP-1)
- Stimulate lipolysis and fat oxidation
- Increase energy expenditure
- Reduce hepatic steatosis
Tirzepatide Mechanism
The GIP component of tirzepatide is theorized to:
- Amplify insulin secretion synergistically with GLP-1
- Enhance adipose tissue function
- Improve lipid metabolism
- Potentially reduce GI side effects
Clinical Trial Data
Survodutide Phase 2 Results
The Phase 2 trial in obesity showed promising results:
| Dose | Weight Loss (48 weeks) |
|---|---|
| 4.8mg | ~18.7% |
| 6.0mg | ~19.5% |
- Significant reductions in liver fat observed
- NAFLD-focused trials showing particular promise
Tirzepatide Phase 3 Results (SURMOUNT)
| Trial | Dose | Weight Loss |
|---|---|---|
| SURMOUNT-1 | 15mg | -22.5% |
| SURMOUNT-2 | 15mg | -15.7% (T2D) |
Efficacy Comparison
| Outcome | Survodutide | Tirzepatide |
|---|---|---|
| Max Weight Loss | ~19.5% (Phase 2) | ~22.5% (Phase 3) |
| Data Maturity | Phase 2 | Phase 3 + approved |
| Liver Fat Reduction | Strong signal | Modest improvement |
| HbA1c Reduction | Significant | -2.3% (15mg) |
Important: Direct comparison is limited as survodutide data is from earlier-phase trials with smaller populations.
NASH/MAFLD Focus
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| NASH Trials | SYNCHRONY (Phase 2b positive) | SYNERGY-NASH (Phase 2) |
| Liver Focus | Primary development pathway | Secondary indication |
| Fibrosis Data | Promising | Early data positive |
Survodutide may have advantages for fatty liver disease due to glucagon’s effects on hepatic lipid metabolism.
Side Effect Profile
Gastrointestinal Effects
| Side Effect | Survodutide | Tirzepatide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Constipation | Less common | Common |
Unique Considerations
| Concern | Survodutide | Tirzepatide |
|---|---|---|
| Blood Glucose | Glucagon may transiently raise | Glucose-lowering |
| Heart Rate | Data emerging | Modest increase |
| Pancreatitis Risk | Unknown (monitoring) | Low (monitored) |
Regulatory and Development Status
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| Phase | Phase 3 | Approved |
| Obesity Approval | Pending | Yes (Zepbound) |
| T2D Approval | Pending | Yes (Mounjaro) |
| NASH Indication | Primary focus | Under investigation |
| First Approval | Expected 2025-2026 | 2022 |
Evidence Quality
| Factor | Survodutide | Tirzepatide |
|---|---|---|
| Trial Phase | Phase 2-3 | Phase 3 complete |
| Sample Sizes | Hundreds | Thousands |
| Duration | Up to 48 weeks | Up to 72 weeks |
| CV Outcomes | Not yet studied | Ongoing |
| Real-World Data | None | Emerging |
Cost and Access
| Factor | Survodutide | Tirzepatide |
|---|---|---|
| Availability | Not available (trials only) | Widely available |
| List Price | Unknown | ~$1,000/month |
| Insurance | N/A | Variable coverage |
Summary
| Factor | Survodutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1/Glucagon | GIP/GLP-1 |
| Evidence Level | High (Phase 2-3) | High (Phase 3 + approved) |
| Weight Loss | ~19% (Phase 2) | ~22% (Phase 3) |
| Unique Strength | Liver fat reduction | Proven efficacy + availability |
| Availability | Investigational | FDA approved |
Key Takeaways
- Different dual mechanisms: Survodutide adds glucagon while tirzepatide adds GIP to the GLP-1 foundation
- Tirzepatide is proven: FDA-approved with extensive Phase 3 data and real-world experience
- Survodutide shows promise: Strong Phase 2 results, especially for liver disease
- Liver disease potential: Survodutide may have advantages for NASH/MAFLD
- Cannot directly compare: Different trial phases and populations limit head-to-head conclusions
This comparison is for educational purposes only. Survodutide is investigational and not approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.